Displaying one session

Controversy Session Arterial Intervention
Time (CEST):
11:30 - 12:30
Date:
Sat, Sep 25, 2021
Channel:
Dotter
Moderator/s:
  • R. Sachar (Raleigh, US)
  • U. Teichgräber (Jena, DE)

201.1 - Paclitaxel-based technologies are dangerous – pro

Presenter:
  • M. Lee (Dublin, IE)
Learning Objectives:
1. To calculate the potential risk of paclitaxel
2. To select patients not suitable for paclitaxel
3. To interpret current trial data

201.2 - Paclitaxel-based technologies are dangerous – con

Presenter:
  • G. Tepe (Rosenheim, DE)
Learning Objectives:
1. To calculate the potential benefits of paclitaxel
2. To select patients suitable for paclitaxel
3. To interpret current trial data

201.3 - Drug-dosage is irrelevant – pro

Presenter:
  • C. Pena (Miami, US)
Learning Objectives:
1. To interpret differences in drug-dose
2. To interpret DCB trial results
3. To discriminate dose differences

201.4 - Drug-dosage is irrelevant – con

Presenter:
  • E. A. Secemsky (Boston, US)
Learning Objectives:
1. To interpret differences in drug-dose
2. To interpret DCB trial results
3. To discriminate dose differences

201.5 - Sirolimus will replace paclitaxel – pro

Presenter:
  • T. Albrecht (Berlin, DE)
Learning Objectives:
1. To interpret the potential power of sirolimus
2. To select patients potentially suitable for sirolimus
3. To discriminate pharmacological differences

201.6 - Sirolimus will replace paclitaxel – con

Presenter:
  • M. Palena (Cotignola, IT)
Learning Objectives:
1. To interpret the potential unmet needs and limitations of sirolimus
2. To select patients not suitable for sirolimus
3. To discriminate pharmacological differences